



ASSIGNMENTS

The assignments or Report writing should enable students to see the purpose for their study and some definite objectives to be achieved. The objectives of the lesson are essential in giving direction and definiteness to the pupils' thought and activities.

The procedure to be followed by the students in doing the work assigned must be explained by the teacher to make the study period effective. The purpose of the lesson assigned must be made known to the students and be recognized by them so that their interest may be stimulated. This refers to the integration of the past and the new lesson or to the principles of the appreciative learning. The psychological principle of apperception is thus given full recognition in the assignment function. Where the elements of appreciative experience are present, the teacher needs to direct the students in the use of such for interpretive purposes.

Another important function of the assignments or Report writing is the recognition of individual differences. All studies in mental measurements agree that among students there exist vast differences in intelligence, aptitudes, and temperaments. Even interests of students are found to be widely divergent. Students work with more vigour, ease, and pleasure when the things they do are in conformity with their interests. It is, therefore, exceedingly important that the assignment provides for these varied interest, aptitudes, and abilities of the pupils.

GRADING RUBRICS FOR REPORT WRITING/ASSIGNMENT

| GRADING ➔ | EXCELLENT QUALITY (5) | CONSIDERABLE QUALITY (4) | ADEQUATE QUALITY (3) | INCONSISTENT QUALITY (2) | UNSATISFACTOR Y QUALITY (1) |
|---|---|---|--|---|--|
| FORMAT/ LAYOUT | Follows formal report conventions, Follows formal report conventions, Prefatory parts, Parallel headings, Supplementary parts Demonstrates an effective layout. | Follows all but one of the formal report conventions, Demonstrates an Effective layout. | Reveals two format errors Applies convention incorrectly/ incompletely | Reveals three format errors, Applies convention incorrectly / incompletely | Non-presentable because of numerous format errors, Applies convention incorrectly/ incompletely |
| CONTENT/STR UCTURE: INTRODUCTION | Exhibits all of following characteristic: Begins with background / definition, Explains purpose, Describes scope and limitations of report, Offers a preview of the findings | Exhibits two errors in content/ structure: Begins with background /definition, Explains purpose, Describes scope and limitations of report Offers a preview of the findings | Reveals three errors in content/ structure: Provides partial background/ definition, Omits the purpose, Does not establish scope and limitations of | Demonstrates four major weaknesses: Provides a weak background/ definition Omits the purpose Does not establish scope and limitations of report Omits preview of findings | Demonstrates the following multiple weaknesses: Provides an ineffective background/definition, Omits the purpose Does not establish scope and limitations of report, Omits preview of findings |





Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bldhannagar, Durgapur-713206, West Bengal (India)

| | | | | | | |
|---|---|---|---|---|--|-----------|
| | | | report, Provides only a partial preview of findings | | | |
| CONTENT / STRUCTURE: BODY | Discusses topic thoroughly and objectively, Use logical order to present information, Provides facts and figures, Uses appropriate length | Discusses topic adequately and objectively, Use logical order to present information, Provides facts and figures, Uses appropriate length | Discusses topic inconsistently Is sometimes vague Shows inconsistent organization Is too short/long | Does not discuss topic is vague, confusing Shows inconsistent organization Is too short/long | No discussion of topic Is cryptic, vague Shows no organization Is too short/long | |
| CONTENT / STRUCTURE: CLOSING /RESULTS / CONCLUSION | Includes an effective summary of data presented, Draws conclusions, that are analytical, based on complete data, Recommends action, based on findings, Ends courteously, professionally Facilitates quick response based on need, data | Includes an effective summary of data presented, Draws conclusions, that are analytical, data somewhat complete Recommends action, partially based on findings Ends courteously Facilitates quick response based on need only | Includes a partial summary Draws partial conclusions, from data not presented Partial personalized ending Partial action close Partial facilitated response | Omits an effective summary Draws partial conclusions based on hearsay, not data Does not personalize ending Action close confusing Confusing facilitated response | Omits an effective summary of any kind Draws no conclusions Makes no recommendations No personalize ending Omits action close Does not facilitate response | |
| GRAMMAR/ SPELLING | Shows effective use of proof- reading and editing: Eliminates all but a few minor errors in grammar, spelling, punctuation, acronym usage, and capitalization | Exhibits only six of the following errors: Spelling/word choice Mechanics: Sentence errors Pronoun errors Subject/verb Agreement, modifiers Parallel structure Punctuation Capitalization | Reveals seven of the following errors: Spelling/ word choice Mechanics: Sentence errors Pronoun errors Subject/verb agreement, modifiers Parallel structure Punctuation Capitalization | Affects credibility due to the following eight errors: Spelling/word choice mechanics: Sentence errors Pronoun errors Subject/verb agreement, modifiers Parallel structure Punctuation Capitalization | Is far too brief for adequate evaluation Affects credibility due to: Spelling/word choice Mechanics: Sentence errors Pronoun errors Subject/verb agreement, Modifiers Parallel structure Punctuation Capitalization | |
| | | | | TOTAL | 1 | 25 |





DR. B.C.ROY COLLEGE OF PHARMACY & AHS, DURGAPUR

B. Pharm. 2nd Year 3rd Semester, AY:
2023-2024

COURSE: B.PHARM

CA: 1ST

PAPER: Pharmaceutical Organic Chemistry II Theory
PT 314 Time: 35 mins

CODE:

Full Marks: 25

WRITE THE ASSIGNMENT IN AN A4 PAPER AND SUBMIT THE SCANNED COPY
RENAMED WITH YOUR UNIVERSITY ROLL NO & NAME. LINK WILL BE GIVEN
AT TIME.

| Assignment Topics: | Map. CO | Marks | |
|---|------------|-------------|-------|
| 1. What is Polynuclear Aromatic Hydrocarbons (PAHs). Explain different preparations and reactions of Naphthalene. Or, | CO-1 | 25 | |
| 2. Compare the aromaticity and reactivity among three PAHs: Naphthalene, Anthracene and Phenanthrene. Write down few reactions of Anthracene and Phenanthrene. Or, | CO-1 | 25 | |
| 3. Write a short note on the applications of Polynuclear Aromatic Hydrocarbons (PAHs) in pharmaceutical technology. | CO-1 | 25 | |
| Assignment & CO MAPPING | CO | NO OF QUES. | MARKS |
| | CO 1 | 3 | 75 |
| | | | |
| | | | |
| | Total | 3 | 75 |

B. Pharm. 2nd Year 3rd Semester, AY:
2023-2024

COURSE: B. Pharm.
PAPER: Pharmaceutical Engineering
Time: 35 minutes

CA: 1ST

CODE: PT- 317

Full Marks: 25

3

ACCREDITED BY NAAC (B++) & NBA (FOR UG PHARMACY) [2023-2026], P. D. (J.U.)

Prof. (Dr.) Samir Kumar Samanta
Principal
Dr. B. C. Roy College of Pharmacy & AHS
Durgapur, West Bengal-713206





WRITE THE ASSIGNMENT IN AN A4 PAPER AND SUBMIT THE SCANNED COPY RENAMED WITH YOUR UNIVERSITY ROLL NO & NAME. LINK WILL BE GIVEN AT TIME.

| Assignment/Topic | Map. CO | Marks | |
|--|-------------|-------------|-------|
| 1. State and explain Fourier's law of heat transmission with equation. 2. Compare the relation between moisture content, stickiness and toughness to size reduction. 3. Explain the importance of drying in the pharmaceutical industry with examples. | 1 2 1 | 25 | |
| ASSIGNMENT AND CO. MAPPING | CO | NO OF QUES. | MARKS |
| | CO. 1 | 2 | 50 |
| | CO. 2 | 1 | 25 |
| | CO. 3 | | |
| | CO. 4 | | |
| | CO. 5 | | |
| TOTAL | 3 | 75 | |

B. Pharm. 2nd Year 3rd Semester, AY:
2023-2024

Corse: B. Pharm.

Paper: Pharmaceutical Microbiology

Time: 35 minutes


Code: PT 319.

CA: 1ST

Full Marks: 25

WRITE THE ASSIGNMENT IN AN A4 PAPER AND SUBMIT THE SCANNED COPY RENAMED WITH YOUR UNIVERSITY ROLL NO & NAME. LINK WILL BE GIVEN AT TIME.

| Assignment/Topic | Map. CO | Marks |
|---|------------|-------|
| 1. What solid plate indicator media will you prepare for identification and cultivation of <i>Escherichia coli</i> ? Design its composition, method for preparation and its terminal sterilization before pouring in petri-dishes. | 1 & 2 | 25 |
| 2. As far as your knowledge goes about the anatomy of bacteria, you have to interpret its impact to improve public health and pharmaceutical industry as well. Write it in a precise manner (within 250 words), step by step with suitable logic for every point. | 2 & 3 | 25 |
| 3. Compare biogenesis vs. abiogenesis from historical point of view and justify the experiments carried out by Koch and Pasteur to develop germ theory of disease. | 1 | 25 |





| ASSIGNMENT AND CO. MAPPING | CO | NO OF QUES. | MARKS |
|----------------------------|-------|-------------|-------|
| | CO. 1 | 1.5 | 37.5 |
| | CO. 2 | 1 | 25 |
| | CO. 3 | 0.5 | 12.5 |
| | CO. 4 | | |
| | CO. 5 | | |
| | TOTAL | 3 | 75 |

**B. Pharm. 2nd Year 3rd Semester, AY:
2023-2024**

Corse: B. Pharm.

CA: 1ST

Paper: Physical Pharmaceutics I Theory


Code: PT 316.

Time: 35 minutes

Full Marks: 25

WRITE THE ASSIGNMENT IN AN A4 PAPER AND SUBMIT THE SCANNED COPY RENAMED WITH YOUR UNIVERSITY ROLL NO & NAME. LINK WILL BE GIVEN AT TIME.

| Q. No | Question | Map. CO | Marks |
|-------|--|----------------------|-------------|
| 1 | "Explain the application of surfactants to Pharmaceuticals and justify the role of surfactants". | CO-2 | 25 |
| 2 | 1. a. At 27°C, a solid is to be ground so that the final particle size is 0.021µm. Estimate the percentage increase in solubility. Assuming that the surface tension of the solid is 100 dynes/cm and the volume per mole is 50 cm ³ . b. It is noted that solubility of the above solute is decreasing with the addition of salt. Describe the phenomena that happened here. | CO-3 CO-4 | 3 3 |
| | 2. a. The solubility of a drug X in a solvent mixture contains 10% by volume of solvent A and 90% by volume of solvent B is 1.8 mg/mL at 25°C. Evaluate (a) molarity, (b) molality, and (c) mole fraction of X. Given, the density of the solvent A is 1.0313 g/ml, the solution is 1.0086 g/ml, solvent B is 0.9970 g/ml, the solvent mixture is 1.0082 g/ml. The molecular weight of drug X is 280.32 g/mole, that of solvent A is 88.10, and that of solvent B is 18.015. b. This drug X begins to separate out from the solution as the pH of the aqueous solution is lowered. Identify the kind of drug X and also justify your answer. | CO-3 CO-4 CO-3 | 9 5 5 |





Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

| | | | | |
|--|--|-----------|--------------------|--------------|
| | c. It is observed that A solvent blend made of 20% V/V of S1 (δ :13.0 H) and 80% V/V of S2 (δ :23.4 H) is used to obtain maximum solubility of drug X. Predict the ideal solubility parameter of Drug X. | | | |
| 3 | 1. Oleic acid is insoluble in water and tartaric acid is more soluble in water than glycerol and propylene glycol. Justify the statement. | CO-4 | 6 | |
| | 2. Oils and fats dissolve in carbon tetrachloride, benzene etc. Explain how these solute molecules interact with the solvent molecules in order to form solution. | CO-4 | 5 | |
| | 3. Miscibility of tertiary butyl alcohol is better than normal and secondary butyl alcohol. Explain the reason behind the above phenomena. | CO-4 | 4 | |
| | 4. Describe the characteristics of polar solvents and discuss about their mechanism of solvent action. | CO-4 | 7 | |
| | 5. Suppose a drug is having solubility 10 mg/ ml in water at 25°C. Designate the drug according to the solubility definition mentioned in the United States Pharmacopoeia. | CO-2 | 3 | |
| Question paper and Mapping with course outcome | | CO | NO OF QUES. | MARKS |
| | | CO. 1 | | |
| | | CO. 2 | 2 | 28 |
| | | CO. 3 | 3 | 17 |
| | | CO. 4 | 6 | 30 |
| | | TOTAL | 3 | 75 |

B. Pharm. 2nd Year 3rd Semester, AY:
2023-2024

Corse: B. Pharm.

Paper: Computer Application in Pharmacy

Time: 35 minutes


CA: 1ST

Code: PT 381.

Full Marks: 25

WRITE THE ASSIGNMENT IN AN A4 PAPER AND SUBMIT THE SCANNED COPY RENAMED WITH YOUR UNIVERSITY ROLL NO & NAME. LINK WILL BE GIVEN AT TIME.

| Assignment/Topic | Map. CO | Marks |
|------------------|---------|-------|
|------------------|---------|-------|






Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bldhannagar, Durgapur-713206, West Bengal (India)

| | | | |
|----------------------------|-------|-------------|-------|
| ASSIGNMENT AND CO. MAPPING | CO | NO OF QUES. | MARKS |
| | CO. 1 | 1 | 25 |
| | CO. 2 | 1 | 25 |
| | CO. 3 | 1 | 25 |
| | CO. 4 | | |
| | CO. 5 | | |
| TOTAL | 3 | 75 | |

Dr. B. C. Roy College of Pharmacy and Allied Health Sciences
Durgapur - 713206
B. Pharm. 2nd yr 3rd Semester' 2023-2024
GRADE SHEET CONTINUOUS EVALUATION 1 (CA1)


| PAPER: Pharmaceutical Engineering | | | | | CODE: PT 317 | | | |
|-----------------------------------|--------------------|---------------------|-----------------|-----------------------------------|---------------------------|---|--------------------|------------|
| SL NO | UNIVERSITY ROLL NO | NAME OF THE STUDENT | FORMAT / LAYOUT | CONTENT / STRUCTURE: INTRODUCTION | CONTENT / STRUCTURE: BODY | CONTENT / STRUCTURE: CLOSING / RESULTS / CONCLUSION | GRAMMAR / SPELLING | TOTAL (25) |
| 1 | 18901922001 | MADHURIMA KUNDU | 5 | 4 | 5 | 4 | 5 | 23 |
| 2 | 18901922002 | MANOJ KUMAR | 4 | 4 | 5 | 5 | 4 | 22 |
| 3 | 18901922003 | TUTUN MANDAL | 5 | 4 | 4 | 4 | 4 | 21 |
| 4 | 18901922004 | SHAMPA GHOSH | 5 | 4 | 5 | 4 | 5 | 23 |
| 5 | 18901922005 | MD TOHID ANSARI | 5 | 4 | 5 | 4 | 5 | 23 |
| 6 | 18901922006 | JEET CHINA | 5 | 4 | 4 | 4 | 4 | 21 |
| 7 | 18901922007 | OINDRILA | 5 | 5 | 5 | 4 | 5 | 25 |



ACCREDITED BY NAAC (B++) & NBA (FOR UG PHARMACY) [2023-2026]
Prof. (Dr.) Samir Kumar Samanta
B. Pharm., Ph.D (J.U.)
Principal
Dr. B. C. Roy College of Pharmacy & AHS
Durgapur, West Bengal-713206



| | 7 | NAG | | | | | | |
|----|-----------------|----------------------------|---|---|---|---|---|----|
| 8 | 1890192200 8 | RAHULDEV MONDAL | 4 | 4 | 4 | 3 | 3 | 18 |
| 9 | 1890192200 9 | SOURAV GORAIN | 4 | 4 | 3 | 4 | 4 | 19 |
| 10 | 1890192201 0 | AKASH ROUTH | 4 | 5 | 5 | 5 | 4 | 23 |
| 11 | 1890192201 1 | NAYAN BISWAS | 4 | 4 | 4 | 5 | 4 | 21 |
| 12 | 1890192201 2 | TATHAGAT DHAL | 5 | 5 | 5 | 4 | 4 | 23 |
| 13 | 1890192201 3 | SURAJ KUMAR PANDIT | 4 | 3 | 4 | 4 | 4 | 19 |
| 14 | 1890192201 4 | PIYALI BEBARTTA | 5 | 5 | 5 | 5 | 4 | 24 |
| 15 | 1890192201 5 | SAMADRITA GHOSH | 5 | 5 | 4 | 5 | 5 | 24 |
| 5 | 1890192201 6 | AVINANDAN KHANDA | 4 | 4 | 4 | 5 | 5 | 22 |
| 17 | 1890192201 7 | SOUMEN KHANRA | 4 | 4 | 5 | 4 | 4 | 21 |
| 18 | 1890192201 8 | RAKHI DHUA | 5 | 4 | 4 | 5 | 4 | 22 |
| 19 | 1890192201 9 | SUBHADIP BANERJEE | 5 | 4 | 5 | 4 | 5 | 23 |
| 20 | 1890192202 0 | SAYAN BHATTACHA RYAY | 4 | 5 | 4 | 5 | 4 | 22 |
| 21 | 1890192202 1 | RITRISHA ADHIKARY | 5 | 5 | 5 | 4 | 4 | 23 |
| 22 | 1890192202 2 | ARKA BEZ | 4 | 4 | 4 | 4 | 4 | 20 |
| 23 | 1890192202 3 | ARNAB SEN | 4 | 4 | 3 | 3 | 4 | 18 |
| 24 | 1890192202 4 | KASTURI PAL | 4 | 4 | 4 | 5 | 5 | 22 |
| 25 | 1890192202 5 | KOUSIK DUTTA | 4 | 5 | 4 | 5 | 4 | 22 |
| 26 | 1890192202 6 | SUBHADEEP NAYAK | A | A | A | A | A | A |
| 27 | 1890192202 7 | SUBHAM DEY | A | A | A | A | A | A |
| 28 | 1890192202 8 | SOMENATH PARAMANIK | 5 | 5 | 4 | 4 | 5 | 23 |
| 29 | 1890192202 9 | ANUSHKA PAN | 5 | 4 | 4 | 4 | 4 | 21 |
| 30 | 1890192203 0 | SANDIP MAITY | 3 | 3 | 4 | 3 | 3 | 16 |
| 31 | 1890192203 | YEADUL SK | 3 | 4 | 4 | 4 | 4 | 19 |






Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

| | | | | | | | | |
|----|-----------------|--------------------------------|---|---|---|---|---|----|
| | 1 | | | | | | | |
| 32 | 1890192203 2 | SHANKHA KARMAKAR | 3 | 4 | 4 | 3 | 3 | 17 |
| 33 | 1890192203 3 | SUBHAM DEY | 5 | 5 | 5 | 4 | 4 | 23 |
| 34 | 1890192203 4 | SPANDAN GHOSH | 4 | 4 | 5 | 4 | 4 | 21 |
| 35 | 1890192203 5 | ABHIJIT GHOSH | 4 | 4 | 4 | 4 | 4 | 20 |
| 36 | 1890192203 6 | MUNSHI AMAN SAHEIN | 5 | 4 | 4 | 4 | 5 | 22 |
| 37 | 1890192203 7 | ABHIJIT KHUTIA | 5 | 4 | 5 | 4 | 5 | 23 |
| 38 | 1890192203 8 | TANMOY DATTA | 5 | 5 | 5 | 5 | 4 | 24 |
| 39 | 1890192203 9 | AHON GHOSH | 4 | 4 | 4 | 4 | 4 | 20 |
| 40 | 1890192204 0 | ARYA ROY | 5 | 5 | 4 | 4 | 5 | 23 |
| 41 | 1890192204 1 | JYOTISHKA MONDAL | 4 | 4 | 5 | 5 | 4 | 22 |
| 42 | 1890192204 2 | SOURIK KARMAKAR | 4 | 4 | 3 | 4 | 4 | 19 |
| 43 | 1890192204 3 | GOURANGA ADHIKARI | 5 | 4 | 4 | 5 | 4 | 22 |
| 44 | 1890192204 4 | NAYAN DUTTA | 3 | 4 | 4 | 4 | 4 | 19 |
| 45 | 1890192204 5 | DEEP KARMAKAR | 4 | 5 | 4 | 5 | 4 | 22 |
| 46 | 1890192204 6 | ANISHA SEN | 5 | 4 | 4 | 4 | 5 | 22 |
| 47 | 1890192204 7 | ABHIK KUMAR BISWAS | 4 | 5 | 5 | 4 | 4 | 22 |
| 48 | 1890192204 8 | NEHA BERA | A | A | A | A | A | A |
| 49 | 1890192204 9 | ABHIK SARKAR | 5 | 4 | 5 | 4 | 3 | 21 |
| 50 | 1890192205 0 | HIMADRI SEKHAR MUKHERJEE | A | A | A | A | A | A |
| 51 | 1890192205 1 | ARNAB GORAI | A | A | A | A | A | A |
| 52 | 1890192205 2 | SAYAN KUMAR MISRA | 3 | 3 | 3 | 3 | 3 | 15 |
| 53 | 1890192205 3 | SOUVIK MONDAL | A | A | A | A | A | A |
| 54 | 1890192205 | PRITHWISH | 5 | 5 | 5 | 5 | 4 | 24 |





| | | | | | | | | |
|----|-----------------|---------------------------|---|---|---|---|---|----|
| | 4 | GHOSH | | | | | | |
| 55 | 1890192205 5 | AKASH KUMAR HAZRA | A | A | A | A | A | A |
| 56 | 1890192205 6 | DIBYAJOTI PAL | 4 | 4 | 4 | 4 | 4 | 20 |
| 57 | 1890192205 7 | TRISHA CHATTERJEE | 4 | 5 | 4 | 4 | 4 | 21 |
| 58 | 1890192205 8 | AGNIK KHUTIA | 5 | 4 | 5 | 5 | 4 | 23 |
| 59 | 1890192205 9 | ARNAB FOUZDAR | A | A | A | A | A | A |
| 60 | 1890192206 0 | SURAJEET GHOSH | 4 | 4 | 4 | 4 | 4 | 20 |
| 61 | 1890192206 1 | SHIBAM DAS | 4 | 4 | 5 | 4 | 4 | 21 |
| 62 | 1890192206 2 | RAHUL GORE | 3 | 3 | 3 | 3 | 3 | 15 |
| 63 | 1890192206 3 | SHIB SANKAR KUMAR | 4 | 4 | 5 | 4 | 4 | 21 |
| 64 | 1890192206 4 | PRITAM MANNA | 4 | 4 | 5 | 5 | 4 | 22 |
| 65 | 1890192206 5 | ARPITA PARIA | A | A | A | A | A | A |
| 66 | 1890192206 6 | SAMPRATI MAITY | 4 | 4 | 5 | 5 | 4 | 23 |
| 67 | 1890192206 7 | SUBHAJIT SANTRA | 4 | 4 | 3 | 4 | 4 | 19 |
| 68 | 1890192206 8 | SWARNAVA DEY | A | A | A | A | A | A |
| 69 | 1890192206 9 | KOUSTAV JHA | A | A | A | A | A | A |
| 70 | 1890192207 1 | MD . NASRAT ALI | 4 | 4 | 5 | 4 | 4 | 21 |
| 71 | 1890192207 2 | SANDIP PARAMANIC K | A | A | A | A | A | A |
| 72 | 1890192207 3 | SANDIP METYA | 4 | 4 | 5 | 4 | 4 | 21 |
| 73 | 1890192207 4 | SOUFYADIP MAHATO | 3 | 3 | 4 | 3 | 3 | 16 |
| 74 | 1890192207 5 | DEBJIT CHAKRABAR TI | 4 | 4 | 5 | 5 | 4 | 22 |
| 75 | 1890192207 6 | NILOY GUHA | 3 | 3 | 3 | 4 | 2 | 15 |
| 76 | 1890192207 7 | PRALAY KUMAR PAHARI | 3 | 3 | 5 | 4 | 4 | 19 |





| | | | | | | | | |
|-----|-----------------|--------------------|-----|---|---|---|---|------|
| 77 | 1890192207 8 | SAGNIK BANIK | 4 | 4 | 4 | 4 | 4 | 20 |
| 78 | 1890192207 9 | SAIKAT BISWAS | 3 | 3 | 4 | 3 | 3 | 16 |
| 79 | 1890192208 0 | SOUBHIK MONDAL | 5 | 5 | 5 | 5 | 5 | 25 |
| 80 | 1890192208 1 | SUMAN JANA | 4 | 4 | 5 | 5 | 4 | 23 |
| 81 | 1890192208 2 | RINTU PAL | 5 | 4 | 5 | 5 | 5 | 24 |
| 82 | 1890192208 3 | GOUTAM DUTTA | 3 | 4 | 4 | 3 | 3 | 17 |
| 83 | 1890192208 4 | BISHAL DAS | 4 | 3 | 4 | 4 | 4 | 19 |
| 84 | 1890192208 5 | ARPITA ROY | A | A | A | A | A | A |
| 85 | 1890192208 6 | SAUMYADIP KAYAL | A | A | A | A | A | A |
| 86 | 1890192208 7 | AYAN MONDAL | 4 | 4 | 5 | 5 | 4 | 22 |
| 87 | 1890192208 8 | KUSHAL SAHA | 4 | 4 | 5 | 5 | 5 | 23 |
| 88 | 1890192208 9 | PRITHA BANERJEE | 4.5 | 4 | 5 | 5 | 5 | 23.5 |
| 89 | 1890192209 0 | ANKIT DAS | 4 | 4 | 5 | 5 | 5 | 23 |
| 90 | 1890192209 1 | DEBLEENA GHOSH | 4 | 4 | 5 | 5 | 5 | 23 |
| 91 | 1890192209 2 | CHAYANIKA KUNDU | 4 | 5 | 5 | 5 | 5 | 24 |
| 92 | 1890192209 3 | SOUMYADIP PAL | 4 | 4 | 5 | 4 | 4 | 21 |
| 93 | 1890192209 4 | SHREYA ROUT | 4 | 4 | 4 | 4 | 4 | 20 |
| 94 | 1890192209 5 | SANDIPAN BARMAN | 4 | 4 | 5 | 4 | 4 | 21 |
| 95 | 1890192209 6 | ANIMESH MANDAL | 5 | 4 | 5 | 5 | 5 | 24 |
| 96 | 1890192209 7 | RAHUL GHOSH | A | A | A | A | A | A |
| 97 | 1890192209 8 | GOLAM MAULA | A | A | A | A | A | A |
| 98 | 1890192209 9 | SUBHADEEP HATI | A | A | A | A | A | A |
| 99 | 1890192210 0 | SOUVICK MAITY | 4 | 4 | 5 | 5 | 5 | 23 |
| 100 | 1890192210 1 | BRATIN ROY | 4 | 4 | 5 | 5 | 5 | 23 |
| 101 | 1890192210 2 | SUVAJIT BHUNIA | 4 | 4 | 4 | 5 | 5 | 22 |





| | | | | | | | | |
|---------|-----------------|-------------------|---|---|---|---|---|----|
| 10 2 | 1890192210 3 | SHREYASI MAITI | 4 | 4 | 5 | 5 | 5 | 23 |
| 10 3 | 1890192210 4 | SANTANU DAS | A | A | A | A | A | A |
| 10 4 | 1890192210 5 | JIT SINGHA | 3 | 3 | 4 | 4 | 4 | 18 |

Dr. B. C. Roy College of Pharmacy and Allied Health Sciences
Durgapur - 713206


B. Pharm. 2nd yr 3rd Semester' 2023-2024

GRADE SHEET CONTINUOUS EVALUATION I (CA1)

PAPER: Pharmaceutical Microbiology(Theory)

CODE: PT 319

| SL. NO | UNIVERSITY ROLL NO | NAME OF THE STUDENT | FORMAT/LAYOUT | CONTENT /STRUCTURE : INTRODUCTI ON | CONTENT / STRUCTUR E: BODY | CONTENT/ STRUCTUR E: CLOSING /RESULTS/ CONCLUSI ON | GRAMMA R/ SPELLIN G | TOTA L (25) |
|--------|--------------------|---------------------|---------------|------------------------------------|----------------------------|--|---------------------|-------------|
| 1 | 1.8902E+10 | MADHURIMA KUNDU | 5 | 4 | 4 | 4 | 4 | 21 |
| 2 | 1.8902E+10 | MANOJ KUMAR | 5 | 4 | 4 | 4 | 4 | 21 |
| 3 | 1.8902E+10 | TUTUN MANDAL | 4 | 4 | 4 | 4 | 4 | 20 |
| 4 | 1.8902E+10 | SHAMPA GHOSH | 5 | 5 | 5 | 4 | 4 | 23 |
| 5 | 1.8902E+10 | MD TOHID ANSARI | 5 | 5 | 5 | 4 | 5 | 24 |
| 6 | 1.8902E+10 | JEET CHINA | 5 | 5 | 5 | 4 | 3 | 22 |
| 7 | 1.8902E+10 | OINDRILA NAG | 5 | 5 | 5 | 4 | 5 | 24 |
| 8 | 1.8902E+10 | RAHULDEV MONDAL | 4 | 3 | 3 | 3 | 4 | 17 |
| 9 | 1.8902E+10 | SOURAV GORAIN | 4 | 4 | 4 | 4 | 4 | 20 |
| 10 | 1.8902E+10 | AKASH ROUTH | 5 | 4 | 4 | 4 | 4 | 21 |
| 11 | 1.8902E+10 | NAYAN BISWAS | 4 | 4 | 4 | 4 | 4 | 20 |
| 12 | 1.8902E+10 | TATHAGAT DHAL | 5 | 5 | 5 | 4 | 5 | 24 |
| 13 | 1.8902E+10 | SURAJ KUMAR PANDIT | 5 | 4 | 4 | 4 | 4 | 21 |
| 14 | 1.8902E+10 | PIYALI | 5 | 5 | 5 | 4 | 5 | 24 |





Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

| | | | | | | | | |
|----|------------|----------------------------|---|---|---|---|---|----|
| | | BEBARTTA | | | | | | |
| 15 | 1.8902E+10 | SAMADRITA GHOSH | 5 | 5 | 5 | 4 | 4 | 23 |
| 16 | 1.8902E+10 | AVINANDAN KHANDA | 5 | 4 | 4 | 4 | 4 | 21 |
| 17 | 1.8902E+10 | SOURMEN KHANRA | 4 | 4 | 4 | 4 | 4 | 20 |
| 18 | 1.8902E+10 | RAKHI DHUA | 5 | 5 | 5 | 4 | 3 | 22 |
| 19 | 1.8902E+10 | SUBHADIP BANERJEE | 5 | 4 | 4 | 4 | 4 | 21 |
| 20 | 1.8902E+10 | SAYAN BHATTACHAR YAY | 5 | 5 | 5 | 4 | 4 | 23 |
| 21 | 1.8902E+10 | RITRISHA ADHIKARY | 5 | 5 | 5 | 4 | 3 | 22 |
| 22 | 1.8902E+10 | ARKA BEZ | 5 | 5 | 5 | 4 | 3 | 22 |
| 23 | 1.8902E+10 | ARNAB SEN | 5 | 5 | 5 | 4 | 3 | 22 |
| 24 | 1.8902E+10 | KASTURI PAL | 5 | 5 | 5 | 4 | 3 | 22 |
| 25 | 1.8902E+10 | KOUSIK DUTTA | 5 | 5 | 5 | 4 | 3 | 22 |
| 26 | 1.8902E+10 | SUBHADEEP NAYAK | A | A | A | A | A | A |
| 27 | 1.8902E+10 | SUBHAM DEY | A | A | A | A | A | A |
| 28 | 1.8902E+10 | SOMENATH PARAMANIK | 5 | 5 | 5 | 4 | 3 | 22 |
| 29 | 1.8902E+10 | ANUSHKA PAN | 5 | 5 | 5 | 4 | 4 | 23 |
| 30 | 1.8902E+10 | SANDIP MAITY | 5 | 4 | 4 | 4 | 4 | 21 |
| 31 | 1.8902E+10 | YEADUL SK | 4 | 3 | 3 | 3 | 5 | 18 |
| 32 | 1.8902E+10 | SHANKHA KARMAKAR | 5 | 5 | 5 | 4 | 3 | 22 |
| 33 | 1.8902E+10 | SUBHAM DEY | 5 | 5 | 5 | 4 | 3 | 22 |
| 34 | 1.8902E+10 | SPANDAN GHOSH | 4 | 4 | 4 | 4 | 3 | 19 |
| 35 | 1.8902E+10 | ABHIJIT GHOSH | 5 | 5 | 5 | 4 | 3 | 22 |
| 36 | 1.8902E+10 | MUNSHI AMAN SAHEIN | 5 | 5 | 5 | 4 | 4 | 23 |
| 37 | 1.8902E+10 | ABHIJIT KHUTIA | 5 | 5 | 5 | 4 | 3 | 22 |
| 38 | 1.8902E+10 | TANMOY DATTA | 5 | 5 | 5 | 4 | 3 | 22 |
| 39 | 1.8902E+10 | AHON GHOSH | 5 | 4 | 4 | 4 | 4 | 21 |
| 40 | 1.8902E+10 | ARYA ROY | 5 | 4 | 4 | 4 | 4 | 21 |
| 41 | 1.8902E+10 | JYOTISHKA MONDAL | 5 | 5 | 5 | 4 | 3 | 22 |
| 42 | 1.8902E+10 | SOURIK KARMAKAR | 5 | 4 | 4 | 4 | 4 | 21 |





Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)


| | | | | | | | | |
|----|------------|--------------------------------|---|---|---|---|---|----|
| 43 | 1.8902E+10 | GOURANGA ADHIKARI | 5 | 4 | 4 | 4 | 4 | 21 |
| 44 | 1.8902E+10 | NAYAN DUTTA | 5 | 4 | 4 | 4 | 4 | 21 |
| 45 | 1.8902E+10 | DEEP KARMAKAR | 5 | 5 | 5 | 4 | 3 | 22 |
| 46 | 1.8902E+10 | ANISHA SEN | 5 | 5 | 5 | 4 | 4 | 23 |
| 47 | 1.8902E+10 | ABHIK KUMAR BISWAS | 5 | 4 | 4 | 4 | 4 | 21 |
| 48 | 1.8902E+10 | NEHA BERA | A | A | A | A | A | A |
| 49 | 1.8902E+10 | ABHIK SARKAR | 5 | 4 | 4 | 4 | 4 | 21 |
| 50 | 1.8902E+10 | HIMADRI SEKHAR MUKHERJEE | A | A | A | A | A | A |
| 51 | 1.8902E+10 | ARNAB GORAI | A | A | A | A | A | A |
| 52 | 1.8902E+10 | SAYAN KUMAR MISRA | 5 | 4 | 4 | 4 | 4 | 21 |
| 53 | 1.8902E+10 | SOVIK MONDAL | A | A | A | A | A | A |
| 54 | 1.8902E+10 | PRITHWISH GHOSH | 5 | 5 | 5 | 4 | 3 | 22 |
| 55 | 1.8902E+10 | AKASH KUMAR HAZRA | A | A | A | A | A | A |
| 56 | 1.8902E+10 | DIBYAJOTI PAL | 4 | 4 | 4 | 4 | 3 | 19 |
| 57 | 1.8902E+10 | TRISHA CHATTERJEE | 5 | 5 | 4 | 5 | 5 | 24 |
| 58 | 1.8902E+10 | AGNIK KHUTIA | 5 | 4 | 4 | 4 | 4 | 21 |
| 59 | 1.8902E+10 | ARNAB FOUZDAR | A | A | A | A | A | A |
| 60 | 1.8902E+10 | SURAJEET GHOSH | 5 | 4 | 4 | 4 | 4 | 21 |
| 61 | 1.8902E+10 | SHIBAM DAS | 4 | 4 | 4 | 4 | 4 | 20 |
| 62 | 1.8902E+10 | RAHUL GORE | 4 | 4 | 4 | 4 | 3 | 19 |
| 63 | 1.8902E+10 | SHIB SANKAR KUMAR | 5 | 5 | 5 | 4 | 4 | 23 |
| 64 | 1.8902E+10 | PRITAM MANNA | 4 | 4 | 4 | 4 | 3 | 19 |
| 65 | 1.8902E+10 | ARPITA PARIA | A | A | A | A | A | A |
| 66 | 1.8902E+10 | SAMPRATI MAITY | 4 | 4 | 4 | 4 | 4 | 20 |
| 67 | 1.8902E+10 | SUBHAJIT SANTRA | 4 | 4 | 4 | 4 | 3 | 19 |
| 68 | 1.8902E+10 | SWARNAVA DEY | A | A | A | A | A | A |





Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)


| | | | | | | | | |
|----|-------------|----------------------|---|---|---|---|---|----|
| 9 | 18901922009 | SOURAV GORAIN | 4 | 4 | 3 | 4 | 4 | 19 |
| 10 | 18901922010 | AKASH ROUTH | 5 | 4 | 4 | 4 | 5 | 22 |
| 11 | 18901922011 | NAYAN BISWAS | 4 | 4 | 5 | 4 | 5 | 22 |
| 12 | 18901922012 | TATHAGAT DHAL | 5 | 4 | 4 | 4 | 5 | 22 |
| 13 | 18901922013 | SURAJ KUMAR PANDIT | 5 | 4 | 5 | 4 | 5 | 23 |
| 14 | 18901922014 | PIYALI BEBARTTA | 4 | 5 | 5 | 5 | 5 | 24 |
| 15 | 18901922015 | SAMADRITA GHOSH | 5 | 4 | 5 | 5 | 5 | 24 |
| 16 | 18901922016 | AVINANDAN KHANDA | 5 | 4 | 4 | 4 | 5 | 22 |
| 17 | 18901922017 | SOUMEN KHANRA | 4 | 5 | 5 | 3 | 4 | 21 |
| 18 | 18901922018 | RAKHI DHUA | 4 | 5 | 4 | 4 | 4 | 21 |
| 19 | 18901922019 | SUBHADIP BANERJEE | 4 | 5 | 3 | 5 | 4 | 21 |
| 20 | 18901922020 | SAYAN BHATTACHA RYAY | 5 | 4 | 4 | 4 | 5 | 22 |
| 21 | 18901922021 | RITRISHA ADHIKARY | 5 | 4 | 5 | 4 | 5 | 23 |
| 22 | 18901922022 | ARKA BEZ | 4 | 5 | 3 | 4 | 4 | 20 |
| 23 | 18901922023 | ARNAB SEN | 3 | 4 | 3 | 3 | 3 | 16 |
| 24 | 18901922024 | KASTURI PAL | 3 | 3 | 3 | 3 | 3 | 15 |
| 25 | 18901922025 | KOUSIK DUTTA | 3 | 2 | 3 | 3 | 3 | 14 |
| 26 | 18901922026 | SUBHADEEP NAYAK | A | A | A | A | A | A |
| 27 | 18901922027 | SUBHAM DEY | A | A | A | A | A | A |
| 28 | 18901922028 | SOMENATH PARAMANIK | 4 | 5 | 4 | 4 | 4 | 21 |
| 29 | 18901922029 | ANUSHKA PAN | 5 | 4 | 5 | 4 | 5 | 23 |
| 30 | 18901922030 | SANDIP MAITY | 5 | 4 | 4 | 4 | 5 | 22 |
| 31 | 18901922031 | YEADUL SK | 3 | 2 | 3 | 3 | 3 | 14 |
| 32 | 18901922032 | SHANKHA KARMAKAR | 4 | 5 | 3 | 4 | 4 | 20 |





Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

| | | | | | | | | |
|----|-------------|--------------------------|---|---|---|---|---|----|
| 33 | 18901922033 | SUBHAM DEY | 4 | 4 | 3 | 5 | 4 | 20 |
| 34 | 18901922034 | SPANDAN GHOSH | 4 | 5 | 3 | 4 | 4 | 20 |
| 35 | 18901922035 | ABHIJIT GHOSH | 3 | 2 | 3 | 3 | 3 | 14 |
| 36 | 18901922036 | MUNSHI AMAN SAHEIN | 5 | 4 | 4 | 4 | 5 | 22 |
| 37 | 18901922037 | ABHIJIT KHUTIA | 5 | 4 | 5 | 4 | 5 | 23 |
| 38 | 18901922038 | TANMOY DATTA | 5 | 4 | 5 | 5 | 5 | 24 |
| 39 | 18901922039 | AHON GHOSH | 3 | 3 | 3 | 4 | 2 | 15 |
| 40 | 18901922040 | ARYA ROY | 5 | 4 | 5 | 4 | 5 | 23 |
| 41 | 18901922041 | JYOTISHKA MONDAL | 4 | 5 | 3 | 4 | 3 | 19 |
| 42 | 18901922042 | SOURIK KARMAKAR | 5 | 4 | 4 | 4 | 5 | 22 |
| 43 | 18901922043 | GOURANGA ADHIKARI | 5 | 4 | 4 | 4 | 5 | 22 |
| 44 | 18901922044 | NAYAN DUTTA | 5 | 4 | 5 | 5 | 5 | 24 |
| 45 | 18901922045 | DEEP KARMAKAR | 4 | 3 | 3 | 4 | 2 | 16 |
| 46 | 18901922046 | ANISHA SEN | 4 | 5 | 5 | 4 | 5 | 23 |
| 47 | 18901922047 | ABHIK KUMAR BISWAS | 5 | 4 | 5 | 4 | 5 | 23 |
| 48 | 18901922048 | NEHA BERA | A | A | A | A | A | A |
| 49 | 18901922049 | ABHIK SARKAR | 5 | 4 | 4 | 4 | 4 | 21 |
| 50 | 18901922050 | HIMADRI SEKHAR MUKHERJEE | A | A | A | A | A | A |
| 51 | 18901922051 | ARNAB GORAI | A | A | A | A | A | A |
| 52 | 18901922052 | SAYAN KUMAR MISRA | 4 | 5 | 4 | 4 | 4 | 21 |
| 53 | 18901922053 | SOUVIK MONDAL | A | A | A | A | A | A |
| 54 | 18901922054 | PRITHWISH GHOSH | 5 | 4 | 5 | 4 | 5 | 23 |
| 55 | 18901922055 | AKASH KUMAR HAZRA | A | A | A | A | A | A |





Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

| | | | | | | | | |
|----|-------------|---------------------------|---|---|---|---|---|----|
| 56 | 18901922056 | DIBYAJOTI PAL | 3 | 2 | 3 | 2 | 2 | 12 |
| 57 | 18901922057 | TRISHA CHATTERJEE | 4 | 5 | 4 | 4 | 4 | 21 |
| 58 | 18901922058 | AGNIK KHUTIA | 5 | 4 | 4 | 4 | 5 | 22 |
| 59 | 18901922059 | ARNAB FOUZDAR | A | A | A | A | A | A |
| 60 | 18901922060 | SURAJEET GHOSH | 4 | 5 | 5 | 5 | 5 | 24 |
| 61 | 18901922061 | SHIBAM DAS | 5 | 4 | 5 | 5 | 5 | 24 |
| 62 | 18901922062 | RAHUL GORE | 5 | 4 | 5 | 4 | 5 | 23 |
| 63 | 18901922063 | SHIB SANKAR KUMAR | 5 | 4 | 4 | 4 | 5 | 22 |
| 64 | 18901922064 | PRITAM MANNA | 4 | 5 | 5 | 5 | 5 | 24 |
| 65 | 18901922065 | ARPITA PARIA | A | A | A | A | A | A |
| 66 | 18901922066 | SAMPRATI MAITY | 5 | 4 | 5 | 5 | 5 | 24 |
| 67 | 18901922067 | SUBHAJIT SANTRA | 5 | 4 | 5 | 4 | 5 | 23 |
| 68 | 18901922068 | SWARNAVA DEY | A | A | A | A | A | A |
| 69 | 18901922069 | KOUSTAV JHA | A | A | A | A | A | A |
| 70 | 18901922071 | MD . NASRAT ALI | 4 | 5 | 4 | 4 | 4 | 21 |
| 71 | 18901922072 | SANDIP PARAMANIC K | A | A | A | A | A | A |
| 72 | 18901922073 | SANDIP METYA | 5 | 5 | 5 | 4 | 5 | 24 |
| 73 | 18901922074 | SOUMYADIP MAHATO | 4 | 5 | 3 | 4 | 4 | 20 |
| 74 | 18901922075 | DEBJIT CHAKRABAR TI | 5 | 4 | 4 | 4 | 5 | 22 |
| 75 | 18901922076 | NILOY GUHA | 2 | 1 | 2 | 1 | 1 | 7 |
| 76 | 18901922077 | PRALAY KUMAR PAHARI | 3 | 3 | 3 | 4 | 3 | 16 |
| 77 | 18901922078 | SAGNIK BANIK | 4 | 5 | 3 | 4 | 4 | 20 |
| 78 | 18901922079 | SAIKAT BISWAS | 5 | 4 | 5 | 4 | 5 | 23 |



Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

| | | | | | | | | |
|----|------------|---------------------------|---|---|---|---|---|----|
| 69 | 1.8902E+10 | KOUSTAV JHA | A | A | A | A | A | A |
| 70 | 1.8902E+10 | MD . NASRAT ALI | 4 | 4 | 4 | 4 | 3 | 19 |
| 71 | 1.8902E+10 | SANDIP PARAMANICK | A | A | A | A | A | A |
| 72 | 1.8902E+10 | SANDIP METYA | 4 | 4 | 4 | 4 | 4 | 20 |
| 73 | 1.8902E+10 | SOUMYADIP MAHATO | 5 | 4 | 4 | 4 | 4 | 21 |
| 74 | 1.8902E+10 | DEBJIT CHAKRABART I | 4 | 4 | 4 | 4 | 3 | 19 |
| 75 | 1.8902E+10 | NILOY GUHA | 4 | 4 | 3 | 4 | 3 | 18 |
| 76 | 1.8902E+10 | PRALAY KUMAR PAHARI | 4 | 4 | 4 | 4 | 4 | 20 |
| 77 | 1.8902E+10 | SAGNIK BANIK | 5 | 4 | 4 | 4 | 4 | 21 |
| 78 | 1.8902E+10 | SAIKAT BISWAS | 5 | 4 | 4 | 5 | 4 | 22 |
| 79 | 1.8902E+10 | SOUBHIK MONDAL | 4 | 4 | 4 | 4 | 3 | 19 |
| 80 | 1.8902E+10 | SUMAN JANA | 4 | 4 | 4 | 4 | 3 | 19 |
| 81 | 1.8902E+10 | RINTU PAL | 5 | 5 | 5 | 4 | 4 | 23 |
| 82 | 1.8902E+10 | GOUTAM DUTTA | 4 | 3 | 3 | 3 | 4 | 17 |
| 83 | 1.8902E+10 | BISHAL DAS | 5 | 5 | 5 | 4 | 3 | 22 |
| 84 | 1.8902E+10 | ARPITA ROY | A | A | A | A | A | A |
| 85 | 1.8902E+10 | SAUMYADIP KAYAL | A | A | A | A | A | A |
| 86 | 1.8902E+10 | AYAN MONDAL | 5 | 5 | 5 | 4 | 5 | 24 |
| 87 | 1.8902E+10 | KUSHAL SAHA | 5 | 5 | 5 | 4 | 4 | 23 |
| 88 | 1.8902E+10 | PRITHA BANERJEE | 5 | 5 | 5 | 4 | 4 | 23 |
| 89 | 1.8902E+10 | ANKIT DAS | 5 | 5 | 5 | 4 | 3 | 22 |
| 90 | 1.8902E+10 | DEBLEENA GHOSH | 5 | 5 | 5 | 4 | 4 | 23 |
| 91 | 1.8902E+10 | CHAYANIKA KUNDU | 5 | 5 | 5 | 4 | 4 | 23 |
| 92 | 1.8902E+10 | SOUMYADIP PAL | 5 | 4 | 4 | 4 | 4 | 21 |
| 93 | 1.8902E+10 | SHREYA ROUT | 5 | 4 | 4 | 4 | 4 | 21 |
| 94 | 1.8902E+10 | SANDIPAN BARMAN | 4 | 3 | 3 | 3 | 5 | 18 |
| 95 | 1.8902E+10 | ANIMESH MANDAL | 4 | 3 | 3 | 3 | 5 | 18 |
| 96 | 1.8902E+10 | RAHUL | A | A | A | A | A | A |





Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bldhannagar, Durgapur-713206, West Bengal (India)

| | | GHOSH | | | | | | |
|-----|------------|----------------|---|---|---|---|---|----|
| 97 | 1.8902E+10 | GOLAM MAULA | A | A | A | A | A | A |
| 98 | 1.8902E+10 | SUBHADEEP HATI | A | A | A | A | A | A |
| 99 | 1.8902E+10 | SOUVICK MAITY | 4 | 4 | 4 | 4 | 4 | 20 |
| 100 | 1.8902E+10 | BRATIN ROY | 4 | 4 | 4 | 4 | 4 | 20 |
| 101 | 1.8902E+10 | SUVAJIT BHUNIA | 4 | 4 | 4 | 4 | 4 | 20 |
| 102 | 1.8902E+10 | SHREYASI MAITI | 4 | 4 | 4 | 4 | 4 | 20 |
| 103 | 1.8902E+10 | SANTANU DAS | A | A | A | A | A | A |
| 104 | 1.8902E+10 | JIT SINGHA | 4 | 4 | 4 | 4 | 4 | 20 |

Dr. B. C. Roy College of Pharmacy and Allied Health Sciences

Durgapur - 713206

B. Pharm. 2nd yr 3rd Semester' 2023-2024

GRADE SHEET CONTINUOUS EVALUATION 1 (CA1)

PAPER: PHARMACEUTICAL ORGANIC
CHEMISTRY II


CODE: 314

| SL. NO | UNIVERSITY ROLL NO | NAME OF THE STUDENT | FORMAT/ LAYOUT | CONTENT / STRUCTURE: INTRODUCTION | CONTENT / STRUCTURE : BODY | CONTENT/ STRUCTURE : CLOSING /RESULTS/ CONCLUSION | GRAMMAR / SPELLING | TOTAL (25) |
|--------|--------------------|---------------------|----------------|-----------------------------------|----------------------------|---|--------------------|------------|
| 1 | 18901922001 | MADHURIM A KUNDU | 4 | 4 | 3 | 4 | 3 | 18 |
| 2 | 18901922002 | MANOJ KUMAR | 4 | 5 | 4 | 5 | 4 | 22 |
| 3 | 18901922003 | TUTUN MANDAL | 4 | 5 | 4 | 4 | 4 | 21 |
| 4 | 18901922004 | SHAMPA GHOSH | 4 | 4 | 3 | 4 | 3 | 18 |
| 5 | 18901922005 | MD TOHID ANSARI | 5 | 4 | 5 | 4 | 5 | 23 |
| 6 | 18901922006 | JEET CHINA | 4 | 5 | 5 | 5 | 5 | 24 |
| 7 | 18901922007 | OINDRILA NAG | 5 | 4 | 5 | 5 | 5 | 24 |
| 8 | 18901922008 | RAHULDEV MONDAL | 4 | 4 | 3 | 4 | 3 | 18 |

16

ACCREDITED BY NAAC (B++) & NBA (FOR UG PHARMACY) [2023-2026]

Prof. Dr. Yamir Kumar Samanta
M. Pharm., Ph.D (J.U.)
Principal
Dr. B. C. Roy College of Pharmacy & AHS
Durgapur, West Bengal-713206





Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

| | | | | | | | | |
|-----|-------------|-----------------|---|---|---|---|---|----|
| 79 | 18901922080 | SOUBHIK MONDAL | 5 | 4 | 5 | 4 | 5 | 23 |
| 80 | 18901922081 | SUMAN JANA | 5 | 4 | 5 | 5 | 5 | 24 |
| 81 | 18901922082 | RINTU PAL | 5 | 5 | 5 | 4 | 5 | 24 |
| 82 | 18901922083 | GOUTAM DUTTA | 3 | 4 | 3 | 4 | 3 | 17 |
| 83 | 18901922084 | BISHAL DAS | 4 | 5 | 4 | 4 | 4 | 21 |
| 84 | 18901922085 | ARPITA ROY | A | A | A | A | A | A |
| 85 | 18901922086 | SAUMYADIP KAYAL | A | A | A | A | A | A |
| 86 | 18901922087 | AYAN MONDAL | 4 | 5 | 5 | 4 | 5 | 23 |
| 87 | 18901922088 | KUSHAL SAHA | 5 | 4 | 5 | 4 | 5 | 23 |
| 88 | 18901922089 | PRITHA BANERJEE | 5 | 4 | 4 | 4 | 5 | 22 |
| 89 | 18901922090 | ANKIT DAS | 5 | 4 | 5 | 4 | 5 | 23 |
| 90 | 18901922091 | DEBLEENA GHOSH | 5 | 4 | 3 | 4 | 3 | 19 |
| 91 | 18901922092 | CHAYANIKA KUNDU | 5 | 4 | 5 | 4 | 5 | 23 |
| 92 | 18901922093 | SOUMYADIP PAL | 3 | 3 | 3 | 4 | 3 | 16 |
| 93 | 18901922094 | SHREYA ROUT | 5 | 4 | 5 | 4 | 4 | 22 |
| 94 | 18901922095 | SANDIPAN BARMAN | 5 | 4 | 5 | 4 | 5 | 23 |
| 95 | 18901922096 | ANIMESH MANDAL | 5 | 4 | 4 | 4 | 5 | 22 |
| 96 | 18901922097 | RAHUL GHOSH | A | A | A | A | A | A |
| 97 | 18901922098 | GOLAM MAULA | A | A | A | A | A | A |
| 98 | 18901922099 | SUBHADEEP HATI | A | A | A | A | A | A |
| 99 | 18901922100 | SOUVICK MAITY | 4 | 5 | 5 | 4 | 5 | 23 |
| 100 | 18901922101 | BRATIN ROY | 5 | 4 | 5 | 4 | 5 | 23 |
| 101 | 18901922102 | SUVAJIT BHUNIA | 4 | 5 | 5 | 5 | 5 | 24 |
| 102 | 18901922103 | SHREYASI MAITI | 5 | 4 | 5 | 5 | 5 | 24 |
| 103 | 18901922104 | SANTANU DAS | A | A | A | A | A | A |





Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SO
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

| | | | | | | | | |
|-----|-------------|------------|---|---|---|---|---|----|
| 104 | 18901922105 | JIT SINGHA | 5 | 4 | 4 | 4 | 5 | 22 |
|-----|-------------|------------|---|---|---|---|---|----|

SAMPLE OF ASSIGNMENT

Dr. B. C. Roy College of Pharmacy and Allied Health Sciences
Durgapur - 713206

ASSIGNMENT

NAME: ARYA ROY

YEAR & SEMESTER: 2nd YEAR, 4th SEMESTER

UNIVERSITY ROLL NO: 18901922105

PAPER: PHARMACOLOGY AND PHYTOCHEMISTRY - I THEORY

PAPER CODE: PT-412

DATE: 17.03.2024

Arya Roy
SIGNATURE OF THE STUDENT

24
17/3/24

Topic 1 - Illustrate and categorize natural allergens with specific examples.

Definition - Allergen are irritating agents of allergy. i.e. the substances capable of sensitizing the body in such a way that on unusual exposure causes in hypersensitive persons. Allergen may be biologic, chemical or of synthetic origin. The substances such as pollen, dander, dust etc. are natural allergens. Although the chemical identity of allergen is unknown but most known allergens are protein or glycoprotein and don't have much difference from other immunogen except perhaps being somewhat smaller in size. Most allergen substances are mixture in composition. Allergen from related sources often similar chemically and cross allergenic.

Allergy definition -
The allergy may be defined as a specific immunologic reaction to an immunogen - a normally harmless substance. It is first defined in 1906 by von Pirquet who described allergy as changed or altered reaction in the body of individual. It response to a substance on condition that is harmful to other.

Symptoms - Allergic symptoms, which depend on the substance involved, can affect your airways, sinuses and nasal passages, skin and digestive system. Allergic reactions can range from mild to severe. In some severe cases, allergies can trigger a life-threatening reaction known as anaphylaxis.

Hay fever, also called allergic rhinitis, can cause

- Sneezing
- Itching of the nose, eyes on roof of the mouth
- Runny, stuffy nose.
- Watery, red or swollen eyes.

A food allergy can cause

- Tingling in the mouth.
- Swelling of the lips, tongue, face, or throat.
- Hives or Anaphylaxis.

A drug allergy can cause

- Hives
- Itchy skin
- Rash
- Facial swelling
- Wheezing
- Anaphylaxis.

Following are predisposing factors which make the person hypersensitive to allergens:

1. Hereditary tendency to allergic response.
2. Dysfunction of the endocrine glands.
3. Excess or excitation of sympathetic and parasympathetic nervous system.
4. Disruption of metabolic and catalytic substances.
5. Hepatic dysfunction.
6. Toxic influence.

The allergen can be classified on the basis of types of symptoms, which depend on the shock organs affected by the particular allergen and its mode of entry into the body:-

1. Inhaled allergens
2. Ingestant allergens
3. Injectant allergens
4. Contactant allergens
5. Directant allergens

Types of Allergens:-

(A) Inhaled allergens:- Inhaled allergens are substances in the air that can trigger allergic reaction. They are often tiny particles like pollen, dust mites, pet dander, which we might inhale without realizing.

(B) Ingestant allergen cause allergies:- Ingestant allergens cause allergies by triggering your immune system. When these substances are inhaled the body mistakes them for invaders and responds by releasing chemicals that cause allergic symptoms.

Some common examples of inhaled allergens:-

Some common inhaled allergens include pollen from trees, grasses and weeds, dust mites, mold spores and animal dander from pets such as cats and dogs.

Symptoms of allergies to airborne substances are

Following:-

1. Sneezing often accompanied by a runny or clogged nose.
2. Coughing and postnasal drip.
3. Itching eyes, nose and throat.
4. Watery eyes, conjunctivitis.

(B) Ingestant allergens:- Allergens which are present in food stuff and swallowed are termed ingestant (food allergy). A food allergy is an immune system response to a food. Once the immune system decides that a particular food is harmful, it creates specific antibody to it.

Symptoms of ingestant allergy:- The gastrointestinal symptoms are mainly affected by the food allergen but they also cause skin rash, puffed lips and tongue, migraines, rhinitis or other symptoms like severe eczema of hand and feet. The effects of food allergens are not localized to one organ or area of the body, but it may transfer to other organs by the blood. Also, an atopic dermatitis such as tomato rash, strawberry rash or that caused by eating orange juice, cold liver oil or other vitamins, containing fish liver oil.

Prevention:- Most satisfactory method of combating food allergen is elimination of the offending substance from the diet. Dairy milk allergy is a specific immunologic antibody-antigen reaction due to a lactalbumin because reaction and boiling after high protein. Milk allergy may result in severe





Desmatitis, recurrent skin rashes, hives, eczema and asthma (its susceptibility can be avoided by the use of commercial milk substitutes that are prepared from soybean isolates)

(3) Injectable Allergens - Injunctable allergens cause symptoms similar to those of the antibiotics, e.g. penicillin, cephalosporins and aminoglycosides.

Symptoms -
1) Itching of the palms of the hands and the soles of the feet.
2) Erythema and
3) Swelling of the skin
4) In severe cases anaphylactic shock may occur.

The natural sources of injectable allergens are produced by the stings of bees, hornets and wasps. The allergen injected by the stings of such insects can induce severe local and constitutional reactions sometimes causing death.

In addition to penicillin products, other injectable that may cause allergies are their extract, antitoxin and the glandular products.

(4) Contactant Allergens - A number of plants and their products have been identified as the cause of contact dermatitis in North America belongs to the Anacardiaceae family, primarily the genus Toxicodendron and includes poison ivy, oak and sumac.

Symptoms -
Common symptoms include skin irritation, redness, itching, swelling, rash, blistering and in severe cases hives or eczema.

(1) Infectant Allergen - Allergy caused by the metabolic product of living microorganisms in the human body such as the continual presence of certain types of bacteria, protozoa, moulds, helminthes and other parasites in the body of human being that are responsible for the chronic infection for which patients are not cured. Often the metabolic product of their growth causes some patient sensitized, and the patient may exhibit allergic symptoms, which doesn't disappear positively to routine skin test for inhalant allergen.

Symptoms - Common symptoms are -
1) Sneezing 2) Wheezing 3) Skin rashes
4) Coughing 5) Nasal congestion 6) Hives.

Conclusion - In conclusion, understanding and managing allergies is crucial for promoting health and well-being. By identifying and avoiding allergens, individuals can reduce the risk of allergic reactions and improve their quality of life. Additionally, continued research and education are essential to develop effective strategies for allergen detection, prevention and treatment. Overall, promoting allergen awareness can lead to healthier communities and improved healthcare outcomes.

19/3/24

DR. B. C. ROY COLLEGE OF PHARMACY AND ALLIED HEALTH SCIENCES

1st Phase / B Pharm 2nd Year 1st Sem 2023

Personal Test No. CA-2 Date 28/3/23

Name Arindita Das

SI No / University Roll No. 18301922023

From Pharmaceutical Microbiology Code PT-319

Di. No. 1/23/02/ 0577 Signature of Investigator [Signature]

FOR EVALUATION ONLY (Marks Obtained) Total Marks 25

| Question Number | 1 | 3 | 7 | 9 | 2 | 5 | 25 | Examiner's Signature |
|-----------------|---|---|---|---|---|---|----|----------------------|
| Marks Obtained | 4 | 4 | 5 | 4 | 5 | | 25 | [Signature] |

(START ANSWERING FROM THE SPACE BELOW)

Answer

1) The method that is not used in pure culture preparation is slant tube.

2) Eosin is not a toxic dye.

3) The dye can bind covalently to the amino side chain of the DNA in survival.

4) Not true with respect to aseptic technique - Explain with (CV).

5) The pressure required for sterilization in autoclave is 15 PSI.

2) Critical Population of bacterial culture media = 50
Mean generation time = 20 minutes

Total time = 2 hours = 120 minutes

Time of lag phase = 30 minutes

Time taken for actual growth = total time - time of lag phase = 120 - 30 = 90 minutes


No. of generations = time taken for actual growth / mean generation time = 90 / 20 = 4.5

Final Population, N = N₀(2)ⁿ = 50 x (2)^{4.5} = 50 x 22.387 = 1119.35

Final population after 2 hours = 1119

3) Graph of bacterial growth curve

The graph plots the number of bacteria (log scale) against time. It shows a lag phase, a stationary phase, and a death phase. The stationary phase is labeled 'stationary' and the death phase is labeled 'death'.



Prof. Dr. [Signature] Arindita Samanta
Principal
Dr. B. C. Roy College of Pharmacy & AHS
Durgapur, West Bengal-713206



Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bldhannagar, Durgapur-713206, West Bengal (India)

Day Phase
In this phase, the bacteria starts to adapt itself with the adverse environmental conditions.
The growth rate is not as fast as in the lag phase, but it is not as slow as in the lag phase. The growth rate is maintained by reproduction in some bacteria and death in others.

Log Phase
After the bacteria get adapted to the environmental conditions, the growth rate increases exponentially. The growth rate is called exponential phase.
The optimal logarithmic growth occurs during this phase.
Substantial measurements of the bacteria are taken in this phase.
The rate of growth, development and differentiation of bacteria are highest during this phase.

Stationary Phase
When the rate of growth of bacteria becomes equal to the rate of death, the line of the graph becomes a straight line forming a plateau like region. This condition is known as stationary phase.
The nutritional requirements of bacteria are not met to greater extent during this phase due to their unavailability.
Autolysis and protozoa etc. that helps in the growth of bacteria become limited in source.
A small product accumulation of bacterial excretion.

Death Phase
The scarcity of the nutritional requirements of bacteria during this stationary phase leads to the decrease in the growth rate of bacteria leading to the death phase.


The growth of bacteria starts with the lag phase.

| TEM | SEM |
|---|---|
| TEM stands for Transmission Electron Microscope. | SEM stands for Scanning Electron Microscope. |
| Transmission Electron Microscope shows the electrons that pass through the specimen as their source of illumination. | Scanning electron microscope uses electrons (secondary) emitted from the surface of the specimen as source of illumination. |
| Transmission electron microscope is used to study internal cell structure, structure of proteins, organization of molecules and their organization and also the organization of plasma. | Scanning electron microscope is used to study surface of cells and microorganisms. |

Culture Media provides the nutritional requirements that are essential for the growth of the bacteria. Culture media can be solid, semi-solid or liquid depending upon the consistency.

Selective Culture Media is a type of culture media that allows the growth of a specific type of microorganisms and prevents the growth of all the other microorganisms.
eg - Whole Blood serum Culture Media.

Differential Culture Media is a special type of media that helps to differentiate between the microorganisms growing in that culture media.
eg - MacConkey agar Culture Media.



Prof. (Dr.) Saikat Kumar Samanta
M. Pharm. (J.U.)
Principal
Dr. B.C. Roy College of Pharmacy & AHS
Durgapur, West Bengal-713206



Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

POWER POINT PRESENTATION

PowerPoint presentations are a powerful tool for communication and have become an essential part of business, education, and many other fields. It allows to use visuals like images, graphs, and charts to make the topic more compelling. Visual aids can help to illustrate complex ideas, making them easier to understand and remember. At student level, power point helps to organize thoughts and structure presentation logically, helping to break down information into manageable portion. Moreover, power point presentations can be easily shared and collaborated on. This makes it easier for teams to work together on a project, ensuring that everyone is working in co-ordination contributing to the final product.


Nowadays students make presentations with interactive elements such as hyperlinks, embedded videos, animations together with charts, graphs, and tables. These features make their effort more dynamic and engaging, encouraging audience participation. We at our college encourage the students to represent data as per the university norms with such power point presentations and enhance the professionalism at the young level itself. So that with their deliverable they can put forward their work effectively leaving a lasting impression.

SAMPLE OF PRESENTATION

Experimental Research and Synthesis

7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer

Presented By:-
Souvik Bhandary.
M. Pharm 2nd Year , 4th Semester
Roll No: 18920722005
Dr. B.C. Roy College of Pharmacy and Allied Health Sciences, Durgapur.



Prof. (Dr. Souvik Kumar Samanta
M. Pharm., Ph.D (J.U.)
Principal
Dr. B. C. Roy College of Pharmacy & AHS
Durgapur, West Bengal-713206



Contents:-

- Introduction
- Continuation
- Discovery and Optimization of AR Antagonists
- Experimental Results and SAR
- Compound 7a – Key Findings
- Spectral Data
- Molecular Modelling
- Conclusion
- References
- Thank You

Experimental Results and SAR

- **Experimental Results & SAR:**
- Synthesis of compounds (7a-d)
- Tested on prostate cancer (22Rv1) and breast cancer (MCF-7) cell lines
- Two compounds (7a,7b) showed superior activity
- Compound 7a: highest potency with submicromolar inhibitory activity

- **Compound 7a – Key Findings**
- Enhanced activity due to 3,5-bis-trifluoromethyl group
- Likely causes steric interactions displacing helix 12 from the binding pocket
- Crucial for retaining activity in AR mutants [7-9]


Continuation:-

- **Breast Cancer (BC):**


- ❖ AR is expressed in breast cancer, and its role is still under exploration.
- ❖ The androgen signaling pathway is considered a potential target in breast cancer therapy.
- ❖ The androgen receptor (AR) is prevalent in both estrogen receptor (ER) positive and negative breast cancers.[2,4]

Discovery and Optimization of AR Antagonists


- ❖ Use of computer-aided drug discovery
- ❖ Identification of new AR antagonists with pure antagonist activity
- ❖ Focus on modifying the terminal aromatic group and the 4-position of the coumarin ring



1
IC₅₀ = 5 μM



2
IC₅₀ = 3.76 μM




3
IC₅₀ = 5.09 μM

Structures of chemotype A (represented by compound 1) and chemotype B (represented by compounds 2 and 3).


Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

Synthetic Scheme:



Synthesis of beta keto ethers (7 (a-d)). Reagents and condition: (a) THF, Et₃N, rt, 24 h

Spectral Data :



Mass Spectral Data of highest potency with submicromolar inhibitory activity compound (7a)

m/z 431.1 (M+H⁺):

This peak represents the molecular ion plus a proton (M+H⁺).
The observed m/z (mass-to-charge ratio) of 431.1 suggests that the molecular weight (MW) of the compound is 430.1 g/mol. This is because in electrospraying (ESI) in positive mode, a proton (H⁺) is added to the molecule, increasing the mass by 1 unit.


m/z 453.1 (M+Na⁺):

This peak represents the molecular ion plus a sodium ion (M+Na⁺).
The observed m/z of 453.1 suggests the addition of a sodium ion (Na⁺) to the molecule. The molecular weight (MW) of the compound is again inferred to be 430.1 g/mol since the sodium ion adds approximately 23 units to the mass (430 + 23 = 453).



Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

Continuation:



Mass Spectral Data of 7b


m/z 326.1 (M+H⁺):

This peak represents the molecular ion of the compound plus a proton (M+H⁺). The observed m/z (mass-to-charge ratio) of 326.1 suggests that the molecular weight (MW) of the compound is 324.1 g/mol. This is because in electrospray ionization (ESI) in positive mode, a proton (H⁺) is added to the molecule, increasing the mass by 1 unit.

m/z 347.1 (M+Na⁺):

This peak represents the molecular ion plus a sodium ion (M+Na⁺). The observed m/z of 347.1 suggests the addition of a sodium ion (Na⁺) to the molecule. The molecular weight (MW) of the compound is again inferred to be 324.1 g/mol since the sodium ion adds approximately 23 units to the mass (324 + 23 = 347).

Continuation:



HPLC Data of highest potency with submicromolar inhibitory activity compound(7a)


Peak Results:

| Index | Name | Time[Min] | Quantity [%Area] | Height[Mvu] | Area[Mvu] | Area % [%] |
|-------|---------|-----------|------------------|-------------|-----------|------------|
| 4 | UNKNOWN | 19.07 | 1.17 | 13.0 | 1.6 | 1.168 |
| 3 | UNKNOWN | 19.84 | 1.41 | 19.4 | 2.0 | 1.412 |
| 1 | UNKNOWN | 22.37 | 95.78 | 747.1 | 133.7 | 95.781 |
| 2 | UNKNOWN | 24.81 | 164 | 11.3 | 2.3 | 1.639 |
| Total | | | 100.00 | 790.8 | 139.6 | 100.000 |



Molecular Modelling:-

- Molecular docking studies were used to understand the interactions between the synthesized compounds and the androgen receptor.
- Most active compounds (7a,7b) interactions in AR ligand-binding domain (LBD).
- Hydrogen bonds: Arg 752, Gln 711, Thr 877, Asn 705.
- Hydrophobic interactions with the coumarin moiety.



Docking Images (A&B)

Conclusion:-


- Umbelliferone derivatives, specifically 7-substituted compounds, showed potential as AR antagonists.
- Compound 7a demonstrated significant inhibitory activity in both prostate and breast cancer cell lines.
- The findings provide a basis for further development of these derivatives for the treatment of AR-related cancers.




Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

References:-



1. Gronemeyer, H.; Gustafsson, J.; Laudet, V. *Nat. Rev. Drug Disc.* 2004, 3, 950.
2. Chang, C.; Lee, S.; Yeh, S.; Chang, T. M. *Oncogene* 2014, 33, 3225.
3. McEwan, I. J. *Future Med. Chem.* 2013, 5, 1109.
4. Proverbs-Singh, T.; Feldman, J. L.; Morris, M. J.; Autio, K. A.; Traha, T. A. *Soc. Endocrinol.* 2015, 22, R87.
5. Shen, H. C.; Shanmugasundaram, K.; Simon, N. I.; Cai, C.; Wang, H.; Chen, S.; Baik, S. P.; Rigby, A. C. *Mol. Endocrinol.* 2012, 26, 1838.
6. Voet, A.; Helsen, C.; Zhang, K. Y.; Claessens, F. *ChemMedChem* 2013, 8, 644..
7. Bajorath, J. *Future Med. Chem.* 2014, 6, 1545.
8. Dimova, D.; Heikamp, K.; Stumpfe, D.; Bajorath, J. *J. Med. Chem.* 2013, 56, 3339.
9. Stumpfe, D.; Bajorath, J. *J. Med. Chem.* 2012, 55, 2932.
10. Pereira de Jesus-Tran, K.; Cote, P. L.; Cantin, L.; Blanchet, J.; Labrie, F.; Breton, R. *Protein Sci.* 2008, 15, 987.
11. Madauss, K. P.; Gryglejko, E. T.; Deng, S. J.; Sulpizio, A. C.; Stanley, T. B.; Wu, C.; Short, S. A.; Thompson, S. K.; Stewart, E. L.; Laping, N. J.; Williams, S. P.; Bray, J. D. *Mol. Endocrinol.* 2007, 21, 1068.
12. <http://dx.doi.org/10.1016/j.bmcl.2016.02.088>



Machine learning-structure-based discovery of a novel
chemotype as FXR agonists for potential treatment of
nonalcoholic fatty liver disease



Presented by
Arup Koley
M. Pharm, 2nd year, Pharmaceutical Analysis
Dr. B.C. Roy College of Pharmacy & AHS





Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SO
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

INTRODUCTION

- Non-alcoholic fatty liver disease (NAFLD) is defined as the accumulation of fat in the liver (hepatic steatosis) not related to alcohol consumption. NAFLD is basically metabolic syndrome's hepatic manifestation.
- NAFLD is a progressive disease, which begins with steatosis, develops into nonalcoholic steatohepatitis (NASH), then to fibrosis, and eventually to cirrhosis and hepatocellular carcinoma.
- Farnesoid X receptor (FXR) is a bile acid (BA)-activating nuclear receptor, which is highly expressed in the liver, gall bladder, intestines, and kidney. FXR is widely acknowledged as a promising target for the treatment of liver disorders such as nonalcoholic fatty liver disease (NAFLD), primary biliary cholangitis (PBC).
- A number of research groups are now involved in the design and development FXR partial agonists and this proposal is thoughtfully crafted to exploit the advanced *in silico* modelling techniques coupled with intuitive design, synthetic medicinal chemistry and pharmacological screening to design and develop new lead molecules as FXR partial agonists.

DESIGN STRATEGY

Machine learning:-

- 1242 compounds with hFXR activity values (EC50) were downloaded from the ChEMBL26 database accessed in April 2020).
- Only the compounds with exact EC50 values were kept and the average value was used for every compound with more than one EC50 values. The compounds were classified as active or inactive, based on whether the EC50 values were below 1 μ M.
- Five ML algorithms, i.e. KNN, SVM, RF, XGBoost and DNN, were applied and the classifiers were constructed with Seikit-learn (version 0.21.3) or Keras (version 1.0.8, for DNN).
- According to four models, i.e., MACCS RF, MACCS SVM, Morgan2 RF and Morgan2 SVM, showed excellent performance on both Test set 1 and Test set 2.
- According to Test set 1, their MCCs overpassed 0.6 and the AUCs were over 0.8. Though not as excellent as they performed on Test set 1, the models also showed fairly good classification performance on Test set 2, with the MCCs and AUCs greater than 0.5 and 0.7, respectively.
- The MCCs of the four models are all greater than 0.74, while the AUC values are bigger than 0.95.

| Model Name | Test set 1 | | | | Test set 2 | | | | External data set | | | |
|-----------------|------------|-------|-------|-------|------------|-------|-------|-------|-------------------|-------|-------|-------|
| | Acc | SP | SN | AUC | Acc | SP | SN | AUC | Acc | SP | SN | AUC |
| MACCS KNN | 0.806 | 0.810 | 0.727 | 0.971 | 0.819 | 0.754 | 0.810 | 0.971 | 0.888 | 0.781 | 0.911 | 0.958 |
| MACCS RF | 0.823 | 0.875 | 0.727 | 0.969 | 0.880 | 0.768 | 0.925 | 0.952 | 0.927 | 0.783 | 0.873 | 0.978 |
| MACCS SVM | 0.847 | 0.913 | 0.727 | 0.970 | 0.860 | 0.787 | 0.900 | 0.955 | 0.981 | 0.818 | 0.873 | 0.978 |
| MACCS XGBoost | 0.806 | 0.808 | 0.658 | 0.967 | 0.801 | 0.690 | 0.830 | 0.981 | 0.902 | 0.762 | 0.831 | 0.948 |
| MACCS DNN | 0.774 | 0.813 | 0.705 | 0.912 | 0.872 | 0.759 | 0.825 | 0.921 | 0.838 | 0.728 | 0.822 | 0.917 |
| Morgan2 KNN | 0.871 | 0.925 | 0.610 | 0.980 | 0.910 | 0.753 | 0.900 | 0.972 | 0.991 | 0.800 | 0.858 | 0.988 |
| Morgan2 RF | 0.811 | 0.880 | 0.705 | 0.971 | 0.894 | 0.783 | 0.925 | 0.980 | 0.950 | 0.815 | 0.873 | 0.985 |
| Morgan2 SVM | 0.871 | 0.938 | 0.750 | 0.974 | 0.870 | 0.788 | 0.925 | 0.952 | 0.927 | 0.824 | 0.861 | 0.990 |
| Morgan2 XGBoost | 0.798 | 0.850 | 0.705 | 0.957 | 0.893 | 0.783 | 0.875 | 0.925 | 0.909 | 0.824 | 0.785 | 0.958 |
| Morgan2 DNN | 0.774 | 0.888 | 0.668 | 0.989 | 0.904 | 0.768 | 0.900 | 0.980 | 0.922 | 0.809 | 0.722 | 0.978 |

Table 1. Classification performance of the individual models evaluated on two test sets and one external data set




Prof. (Dr.) Samir Kumar Samanta
M. Pharm., Ph.D (J.U.)
Dr. B.C. Roy College of Pharmacy & AHS
Durgapur, West Bengal-713206




Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bldhannagar, Durgapur-713206, West Bengal (India)

¹³C NMR and Spectra of 2-((S)-1-((2S,4R)-2-methyl-4-(phenylamino)-3,4-dihydroquinolin-1(2H)-yl)-1-oxopropan-2-yl)hexahydro-1H-isoindole-1,3(2H)-dione (XJ02862-S2)



¹³C NMR (101 MHz, Chloroform-d) δ 180.17, 180.12, 169.00, 147.01, 138.22, 135.36, 129.50, 127.94, 126.94, 125.32, 124.37, 118.15, 113.07, 49.76, 49.11, 48.30, 41.13, 40.03, 39.74, 24.15, 23.60, 21.88, 21.30, 13.20

HPLC chromatograms of target compound (XJ02862-S2)



Column: CHIRALPAK AD-3 (250 × 4.6 mm, 3 μ m); eluent: hexane/2-propanol: 75/25; flow rate, 1.0 mL/min; column temperature, 40 °C; detection, 254 nm.
HPLC purity: 99.7%. RT = 7.942 min.

CONCLUSION

FXR plays a crucial role in bile acid, glucose and lipid homeostasis, which has become an attractive target to discover and develop drugs for NAFLD treatment. Due to the severe side effects of OCA as a representative semisynthetic BA derivative, nonsteroidal FXR agonists have received extensive attention from researchers in academia and pharmaceutical industry in recent years. Unfortunately, no FXR agonist has been approved for NAFLD so far. ML based computational approaches can identify potential hits rapidly and effectively, whereas they were rarely applied for the discovery of FXR agonists and the only application merely brought about weakly active chemotypes in vitro



Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

Dr. B. C. Roy College of Pharmacy and AHS

Bidhannagar, Durgapur-06

GRADING RUBRICS FOR CONTINUOUS EVALUATION 3


For Multiple Choice Question

| GRADING | 1 | 0 |
|-------------|---------|-----------|
| Q. NO: 1 | Correct | Incorrect |
| Q. NO: 2 | | |
| Q. NO: 3 | | |
| Q. NO: 4 | | |
| Q. NO: 5 | | |
| Q. NO: 6 | | |
| Q. NO: 7 | | |

For Short Answer Type

| GRADING | 5 | 4 | 3 | 2 | 1 | 0 |
|-------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|---------------------|
| Q. NO: 2 | Mentioned 3 key words | Mentioned 4 key words | Mentioned 3 key words | Mentioned 2 key words | Mentioned 1 key words | Incorrect answer |
| Q. NO: 3 | | | | | | |
| Q. NO: 4 | | | | | | |
| Q. NO: 5 | | | | | | |
| Q. NO: 6 | | | | | | |
| Q. NO: 7 | | | | | | |

Shobhan Bose
(IC_Exam)
BCRCP






Approved by PCI & Affiliated to MAKAUT, WB and WBSCT&VE&SD
Dr. Meghnad Saha Sarani, Bidhannagar, Durgapur-713206, West Bengal (India)

SEMINAR (PRESENTATION) EVALUATION RUBRICS (100 marks) - MPT1986/MPT391

| | Exemplary (17-20 marks) | Proficient (13-16 marks) | Needs Practice (<=12 marks) |
|---------------------------------------|---|--|---|
| Organization (20) | <ul style="list-style-type: none"> The information is in logical, interesting sequence which audience can follow. Uses an engaging beginning and/or thoughtful ending. Moves smoothly from one idea to the next all of the time | <ul style="list-style-type: none"> Student presents information in logical sequence which audience can follow. Uses an appropriate beginning or ending Moves smoothly from one idea to the next some of the time. | <ul style="list-style-type: none"> Sequence of information is difficult to follow. Lacks beginning, middle, and end. Does not move smoothly from one point to another |
| Language use and Delivery (20) | <ul style="list-style-type: none"> Effectively uses eye contact. Speaks clearly, effectively and confidently using suitable volume and pace. Fully engages the audience. Dresses appropriately, Selects rich and varied words for context and uses correct grammar. | <ul style="list-style-type: none"> Maintains eye contact. Speaks clearly and uses suitable volume and pace. Takes steps to engage the audience Dresses appropriately. Selects words appropriate for context and uses correct grammar. | <ul style="list-style-type: none"> Some eye contact, but not maintained. Speaks clearly and unclearly in different portions. Occasionally engages audience. Dresses inappropriately. Selects words inappropriate for context; uses incorrect grammar |
| Content (30) | <ul style="list-style-type: none"> Clearly defines the topic or synopsis and its significance. Supports the synopsis and key findings with an analysis of relevant and accurate evidence Provides evidence of extensive and valid research / review/review with multiple and varied sources. Combines and evaluates existing ideas to form new insights | <ul style="list-style-type: none"> Defines the topic or synopsis. Supports the synopsis with evidence. Presents evidence of research / review with sources. Combines existing ideas | <ul style="list-style-type: none"> Does not clearly define the topic or synopsis. Does not support the synopsis with evidence. Presents little or no evidence of valid research / review. Shows little evidence of the combination of ideas |
| Question and Answer(20) | <ul style="list-style-type: none"> Demonstrates extensive knowledge of the topic by responding confidently, precisely and appropriately to all audience questions and feedback. | <ul style="list-style-type: none"> Demonstrates some knowledge of the topic by responding accurately and appropriately to questions and feedback. | <ul style="list-style-type: none"> Demonstrates incomplete knowledge of the topic by responding inaccurately and inappropriately to questions and feedback. |
| Timeliness (10) | <ul style="list-style-type: none"> Entire presentation was within 15 minutes of allotted time. | <ul style="list-style-type: none"> Entire presentation exceeded 5 minutes of allotted time. | <ul style="list-style-type: none"> Entire presentation was exceeded 10 minutes of allotted time. |



Prof. (Dr.)  Anir Kumar Samanta
M. Pharm., Ph.D (J.U.)
Principal
Dr. B. C. Roy College of Pharmacy & AHS
Durgapur, West Bengal-713206